Susquehanna International Group’s Janux Therapeutics JANX Stock Holding History

Susquehanna International Group’s Portfolio JANX Stock Details JANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.74M	Sell	113,600 -132,200	-54%	-$1.92M	﹤0.01%	6801
2026 Q1	$3.42M	Buy	245,800 +33,300	+16%	+$457K	﹤0.01%	5001
2025 Q4	$2.93M	Buy	212,500 +164,900	+346%	+$3.88M	﹤0.01%	4905
2025 Q3	$1.16M	Sell	47,600 -15,200	-24%	-$370K	﹤0.01%	6996
2025 Q2	$1.45M	Sell	62,800 -48,000	-43%	-$1.26M	﹤0.01%	6529
2025 Q1	$2.99M	Buy	110,800 +2,300	+2%	+$86.7K	﹤0.01%	4654
2024 Q4	$5.81M	Buy	108,500 +28,500	+36%	+$1.51M	﹤0.01%	3379
2024 Q3	$3.63M	Buy	80,000 +25,000	+45%	+$1.09M	﹤0.01%	4180
2024 Q2	$2.3M	Sell	55,000 -23,400	-30%	-$1.1M	﹤0.01%	4821
2024 Q1	$2.95M	Buy	+78,400	New	+$1.71M	﹤0.01%	4553

Other funds holding JANX

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Susquehanna International Group's JANX Position: Q2 2026 in Review

Susquehanna International Group sold out of Janux Therapeutics (JANX) in Q2 2026, closing a stake of 119,055 shares — an estimated $1.72M sold.

Susquehanna International Group first reported a position in JANX in Q1 2023 and held it in 10 quarters. The position peaked at $9.96M in Q1 2025. 197 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

Susquehanna International Group reported no remaining Janux Therapeutics position as of Q2 2026 after selling out during the quarter.
Susquehanna International Group sold 119,055 Janux Therapeutics shares in Q2 2026, an estimated $1.72M.
Susquehanna International Group first reported a position in Janux Therapeutics in Q1 2023 and held it in 10 quarters.
Susquehanna International Group's Janux Therapeutics position peaked at $9.96M in Q1 2025.
197 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.